Qual é o preço para Graphite Bio, Inc. (GRPH)

O preço para Graphite Bio, Inc. (GRPH) é $22.26

Qual é a capitalização de mercado para Graphite Bio, Inc. (GRPH)

A capitalização de mercado para Graphite Bio, Inc. (GRPH) é $553.40M

Histórico de Preços de Graphite Bio, Inc. (GRPH)

Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to developing innovative therapeutic solutions for severe and life-threatening illnesses across the United States. Its primary investigational therapy, GPH101, is an autologous, gene-edited hematopoietic stem cell product specifically engineered to directly correct the underlying mutation causing sickle cell disease, thereby restoring normal adult hemoglobin production. The company's pipeline also features GPH201, intended for the treatment of X-linked severe combined immunodeficiency syndrome, and GPH301, an experimental candidate designed to address Gaucher disease, a genetic disorder characterized by a deficiency in the glucocerebrosidase enzyme. Initially established as Integral Medicines, Inc., the company rebranded to Graphite Bio, Inc. in August 2020. Founded in 2017, Graphite Bio's operations are based out of its headquarters in South San Francisco, California.

Ano	Desempenho
2024	40.75%
2023	-26.18%
2022	-70.69%
2021	0.00%

Ano

Desempenho

2024

40.75%

2023

-26.18%

2022

-70.69%

2021

0.00%

Empresa	Preço da ação	Variação 1a%	País
Vertex Pharmaceuticals Incorporated VRTX.US	$542.09	38.63%	US
Argenx SE ARGX.US	$1.03K	44.13%	NL
CSL Limited CSL.AX	$121.01	-13.08%	AU
Moderna, Inc. MRNA.US	$138.18	473.58%	US
Lonza Group AG LONN.SW	$753.54	6.39%	CH

Empresa

Preço da ação

Variação 1a%

País